http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
MESOGRANULATION AND THE SOLAR SURFACE MAGNETIC FIELD DISTRIBUTION
Yelles Chaouche, L.,Moreno-Insertis, F.,Martí,nez Pillet, V.,Wiegelmann, T.,Bonet, J. A.,Knö,lker, M.,Bellot Rubio, L. R.,del Toro Iniesta, J. C.,Barthol, P.,Gandorfer, A.,Schmidt, W.,Solank IOP Publishing 2011 ASTROPHYSICAL JOURNAL LETTERS - Vol.727 No.2
Chang Yell Shin,Mi Young Jung,In Ki Lee,Miwon Son,Dong Sung Kim,Joong In Lim,Soon Hoe Kim,Moohi Yoo,Tae Lin Huh,Young Taek Sohn,Won Bae Kim 대한약학회 2004 Archives of Pharmacal Research Vol.27 No.1
DA-11004 is a synthetic, potent NADP-dependent isocitrate dehydrogenase (IDPc) inhibitor where IC50 for IDPc is 1.49 mM. The purpose of this study was to evaluate the effects of DA- 11004 on the high fat high sucrose (HF)-induced obesity in male C57BL/6J mice. After completing a 8-week period of experimentation, the mice were sacrificed 1hr after the last DA- 11004 treatment and their blood, liver, and adipose tissues (epididymal and retroperitoneal fat) were collected. There was a significant difference in the pattern of increasing body weight between the HF control and the DA-11004 group. In the DA-11004 (100 mg/kg) treated group the increase in body weight significantly declined and a content of epididymal fat and retroperitoneal fat was also significantly decreased as opposed to the HF control. DA-11004 (100 mg/ kg) inhibited the IDPc activity, and thus, NADPH levels in plasma and the levels of free fatty acid (FFA) or glucose in plasma were less than the levels of the HF control group. In conclusion, DA-11004 inhibited the fatty acid synthesis in adipose tissues via IDPc inhibition, and it decreased the plasma glucose levels and FFA in HF diet-induced obesity of C57BL/6J mice.
Bromocriptine(Parlodel)이 산욕기(產褥期) 유즙분필(乳汁分泌) 억제효과(抑制效果)에 관(關)한 연구(研究)
尹汝霖 ( Yell Rim Yoon ) 대한산부인과학회 1981 Obstetrics & Gynecology Science Vol.24 No.7
A comparative clinical study on the effectiveness of bromocriptine mesylate and steroid hormones in suppressing puerperal lactation was carried out in 25 puerperal women, evaluating clinical findings of milk secretion, breast engorgement and pain, and determining serum prolactin levels. The bromocriptine group of 13 cases received 2. 5mg of bromocriptine twice daily for 2weeks, and the steroid hormone group of 12 cases received a single injection of a depot consisting of 10mg of 17-,β-estradiol cyciopentyl propionate and 250mg of testosterone propionate immediately after birth. An additional 7 patients who breast-fed their babies were included in this study to observe the baseline levels of serum prolactin during the postpartum period. In the steroid group milk secretion was observed in 75% of the patients on the 3rd day postpartum and 42% 1 week postpartum. Whereas none of the cases showed milk secretion on the 3rd day postpartum or 1 week postpartum patients of the bromocriptine group. In the bromocriptine group medication was started 4 to 8 hours after delivery. In the bromocriptine group rebound lactation was observed in 15%. However, it was milk and it stopped in all cases with further treatment of 1 weeks duration The baseline serum prolactin levels in both the lactating and steroid groups were above 200ngjml during the 1st postpartum week.
( Chang Yell Shin ),( Hae-sun Kim ),( Kwang-ho Cha ),( Dong Han Won ),( Ji-yun Lee ),( Sun Woo Jang ),( Uy Dong Sohn ) 한국응용약물학회 2018 Biomolecules & Therapeutics(구 응용약물학회지) Vol.26 No.3
A previous study in humans demonstrated the sustained inhibitory effects of donepezil on acetylcholinesterase (AChE) activity; however, the effective concentration of donepezil in humans and animals is unclear. This study aimed to characterize the effective concentration of donepezil on AChE inhibition and impaired learning and memory in rodents. A pharmacokinetic study of donepezil showed a mean peak plasma concentration of donepezil after oral treatment (3 and 10 mg/kg) of approximately 1.2 ± 0.4 h and 1.4 ± 0.5 h, respectively; absolute bioavailability was calculated as 3.6%. Further, AChE activity was inhibited by increasing plasma concentrations of donepezil, and a maximum inhibition of 31.5 ± 5.7% was observed after donepezil treatment in hairless rats. Plasma AChE activity was negatively correlated with plasma donepezil concentration. The pharmacological effects of donepezil are dependent upon its concentration and AChE activity; therefore, we assessed the effects of donepezil on learning and memory using a Y-maze in mice. Donepezil treatment (3 mg/kg) significantly prevented the progression of scopolamine-induced memory impairment in mice. As the concentration of donepezil in the brain increased, the recovery of spontaneous alternations also improved; maximal improvement was observed at 46.5 ± 3.5 ng/g in the brain. In conclusion, our findings suggest that the AChE inhibitory activity and pharmacological effects of donepezil can be predicted by the concentration of donepezil. Further, 46.5 ± 3.5 ng/g donepezil is an efficacious target concentration in the brain for treating learning and memory impairment in rodents.
( Chang Yell Shin ),( Hak Yeong Lee ),( Gil Hyung Kim ),( Sun Young Park ),( Won Seok Choi ),( Uy Dong Sohn ) 한국응용약물학회 2021 Biomolecules & Therapeutics(구 응용약물학회지) Vol.29 No.4
In this study, we aimed to investigate the effects of 8 weeks of treatment with a combination of evogliptin and leucine, a branchedchain amino acid, in mice with high-fat diet (HFD)-induced diabetes. Treatment with evogliptin alone or in combination with leucine reduced the body weight of the mice, compared to the case for those from the HFD control group. Long-term treatment with evogliptin alone or in combination with leucine resulted in a significant reduction in glucose intolerance; however, leucine alone did not affect postprandial glucose control, compared to the case for the mice from the HFD control group. Furthermore, the combination of evogliptin and leucine prevented HFD-induced insulin resistance, which was associated with improved homeostasis model assessment for insulin resistance, accompanied by markedly reduced liver fat deposition, hepatic triglyceride content, and plasma alanine aminotransferase levels. The combination of evogliptin and leucine increased the gene expression levels of hepatic peroxisome proliferator-activated receptor alpha, whereas those of the sterol regulatory element-binding protein 1 and stearoyl-CoA desaturase 1 were not altered, compared to the case in the HFD-fed mice (p<0.05). Thus, our results suggest that the combination of evogliptin and leucine may be beneficial for treating patients with type 2 diabetes and hepatic steatosis; however, further studies are needed to delineate the molecular mechanisms underlying the action of this combination.